Trial Profile

An Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 29 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMC-002 (Primary) ; Lenvatinib
Indications Advanced breast cancer; Gallbladder cancer; Liver cancer; Male breast cancer; Solid tumours
Focus Adverse reactions
Sponsors ImmuneOncia Therapeutics

15 Jun 2025 Planned number of patients changed from 49 to 62.
15 Jun 2025 Planned End Date changed from 31 Dec 2026 to 30 Aug 2029.
15 Jun 2025 Planned primary completion date changed from 30 Jun 2025 to 17 Dec 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com